Navigation Links
New Race –Specific drug

World's first race-specific medicine has been developed to resolve the controversy over// whether black people are genetically different from whites.

BiDil, a drug combination for treating heart failure, has proved three times more effective in black patients than it has for their white counterparts, its manufacturer claims. If approved by the FDA, it would be the first drug ever to be licensed for use by a single ethnic group.

The results of clinical trials are testament to BiDil's value. In trials, it improved survival rates among black people who had suffered heart failure by 47 per cent. In white patients, the figure was only 15 per cent.

BiDil works by boosting the level of nitrous oxide in the walls of the body's arteries and capillaries, allowing them to expand and thereby reducing the body's blood pressure. In turn, this reduces overall strain on the heart. It proved more effective in African-American patients because they have naturally lower levels of nitrous oxide in their blood and long-term high blood pressure is usually the cause of heart failure.

In contrast, the leading causes of heart failure among white people are clogged arteries and damage to the cardiac muscle caused by previous heart attacks. The issue of whether biological differences can be determined by one's ethnic origins is a long-standing one, and it raises a number of legal and ethical questions. There is a powerful lobby which is in favour of racial profiling when it comes to drug development, backed by evidence that suggests a degree of truth in the ethnicity theory. The reasons for the difference in response to a drug are unclear although it is thought that genes play a major role.

Type-2 diabetes is more common among people from the Indian subcontinent and is thought to be due to a combination of genetic factors and environmental ones. It has also been shown that cases of increased heart weight - an abnormality that can cause heart attacks, heart failure and stroke - is up to three times more prevalent among African-Americans than whites. These exciting results suggest the extent to which even the early stages of heart disease could be prevented in the African-American community by prevention and treatment of hypertension.


'"/>




Related medicine news :

1. Dr Reddy’s Laboratories to challenge patents on drug
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2017)... ... May 26, 2017 , ... ... CareFusion NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware ... for diagnostic device operations. With this platform, initializing devices and importing studies are ...
(Date:5/26/2017)... Sparks, Nevada (PRWEB) , ... May 26, 2017 ... ... to produce the first ever copper, antimicrobial, mesh back 24/7 task chair specifically ... and conference applications. “We are thrilled to partner with Cupron® to provide ...
(Date:5/26/2017)... Texas (PRWEB) , ... May 26, 2017 , ... Yisrayl ... a new publication this week that is focusing on the Peace Agreements being discussed ... his Middle East sprint in a race to try to speed up peace talks ...
(Date:5/26/2017)... Francisco, CA (PRWEB) , ... May 26, 2017 , ... ... Francisco, is proud to announce a new, informational blog post on insurance options. If ... surgery, checking insurance plans may help save time and money. Visiting an in-network provider ...
(Date:5/26/2017)... ... 26, 2017 , ... Centennial-based BluSky Restoration Contractors announced that ... Annual Clays for Kids fundraiser, to be held Friday, Sept. 22, at Kiowa ... part of BluSky’s partnership with The Adoption Exchange, BluSky will also share sponsorship ...
Breaking Medicine News(10 mins):
(Date:5/18/2017)...  Two Bayer U.S. Pharmaceutical leaders received top awards ... 28 th Woman of the Year ... longstanding mission of furthering the advancement and impact of ... Cindy Powell-Steffen , senior director of brand activation and ... Libby Howe , a regional business manager for New ...
(Date:5/15/2017)... Inc., a privately-held CNS pharmaceutical company based in ... disease (PD), has enrolled the first patient in the RASMET ... study involving patients with PD and taking place at 12 ... period. The first stage is open label and involves single ... Denver , Boca Raton ...
(Date:5/10/2017)... Inc. (Nasdaq: HOLX ) announced today the ... April 1, 2017 .   GAAP diluted earnings per ... prior year period as the sale of the blood ... diluted EPS of $0.50 increased 6.4%.  Revenue of $715.4 ... Excluding the effects of blood screening and the acquired ...
Breaking Medicine Technology: